Pharvaris N.V. (PHVS)
Last updated: 2026-10-23 21:25:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Pharvaris N.V. (PHVS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $31.44, with a market capitalization of $2.15B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $21.02 to $43.25. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.15B | |
$31.57 | |
$43.25 | |
$1.77 | |
$30.68 | |
580.95K | |
781.10K | |
-- | |
$43.25 | |
$21.02 | |
-- | |
-- |
Pharvaris N.V. (PHVS) After-Hours Stock Price
Pharvaris N.V. (PHVS) is trading at $31.44 in after-hours trading as of 2026-10-23 20:42:00, up 2.46% ($0.75) from the regular-session close of $30.68.
After-hours trading shows how investors are pricing PHVS after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Pharvaris N.V. (PHVS) 7-Day Stock Price Change
Over the past seven days, Pharvaris N.V. (PHVS) moved from $30.02 to $31.44, representing a gain of 4.71% ($1.41).
The stock traded between $27.68 and $32.09 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 745.06 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
PHVS 52-Week Price Position
Position in Range: 46.9%
PHVS is currently trading at $31.44, placing it 46.9% of the way from its 52-week low of $21.02 to its 52-week high of $43.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Pharvaris N.V. (PHVS)?
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Pharvaris N.V. Information
| Employees | 129 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Pharvaris N.V. (PHVS) Stock on MEXC
Eligible investors can buy real shares of Pharvaris N.V. (PHVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Pharvaris N.V. (PHVS) stock price today?
2.Is PHVS stock going up or down today?
3.What is PHVS pre-market price?
4.What is PHVS after-hours price?
5.Is PHVS stock trading now?
6.Where does PHVS sit relative to its 52-week high and low?
7.What sector is Pharvaris N.V. in?
8.What is Pharvaris N.V.'s market capitalization and where is it listed?
9.How is PHVS valued in terms of P/E ratio and EPS?
10.Does Pharvaris N.V. pay a dividend?
Explore More US Stocks
Search Stocks
PHVS Stock Calculator
Estimate the value between PHVS shares and USD.
PHVS Shares to USD
1.00 PHVS shares = 31.435 USD
Calculations are estimates based on the latest available price and are for reference only.


